Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies

Robert Cross; Chad Mire; Luis M. Branco; Joan B. Geisbert; Megan M. Rowland; Megan L. Heinrich; Augustine Goba; Mambu Momoh; Donald S. Grant; Mohamed Fullah; Sheik Humarr Khan; James E. Robinson; Thomas Geisbert; Robert F. Garry

doi:10.1016/j.antiviral.2016.08.012

Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies

Robert Cross, Chad Mire, Luis M. Branco, Joan B. Geisbert, Megan M. Rowland, Megan L. Heinrich, Augustine Goba, Mambu Momoh, Donald S. Grant, Mohamed Fullah, Sheik Humarr Khan, James E. Robinson, Thomas Geisbert, Robert F. Garry

Microbiology And Immunology

Research output: Contribution to journal › Article

26 Scopus citations

Abstract

Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.

Original language	English (US)
Pages (from-to)	218-222
Number of pages	5
Journal	Antiviral Research
Volume	133
DOIs	https://doi.org/10.1016/j.antiviral.2016.08.012
State	Published - Sep 1 2016

ASJC Scopus subject areas

Pharmacology
Virology

Access to Document

10.1016/j.antiviral.2016.08.012

Fingerprint Dive into the research topics of 'Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies'. Together they form a unique fingerprint.

Cite this

Cross, R., Mire, C., Branco, L. M., Geisbert, J. B., Rowland, M. M., Heinrich, M. L., Goba, A., Momoh, M., Grant, D. S., Fullah, M., Khan, S. H., Robinson, J. E., Geisbert, T., & Garry, R. F. (2016). Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antiviral Research, 133, 218-222. https://doi.org/10.1016/j.antiviral.2016.08.012

Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. / Cross, Robert ; Mire, Chad; Branco, Luis M.; Geisbert, Joan B.; Rowland, Megan M.; Heinrich, Megan L.; Goba, Augustine; Momoh, Mambu; Grant, Donald S.; Fullah, Mohamed; Khan, Sheik Humarr; Robinson, James E.; Geisbert, Thomas; Garry, Robert F.

In: Antiviral Research, Vol. 133, 01.09.2016, p. 218-222.

Research output: Contribution to journal › Article

Cross, Robert ; Mire, Chad ; Branco, Luis M. ; Geisbert, Joan B. ; Rowland, Megan M. ; Heinrich, Megan L. ; Goba, Augustine ; Momoh, Mambu ; Grant, Donald S. ; Fullah, Mohamed ; Khan, Sheik Humarr ; Robinson, James E. ; Geisbert, Thomas ; Garry, Robert F. / Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. In: Antiviral Research. 2016 ; Vol. 133. pp. 218-222.

@article{4336b536d4504f748e7031f0348c5b06,

title = "Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies",

abstract = "Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.",

author = "Robert Cross and Chad Mire and Branco, {Luis M.} and Geisbert, {Joan B.} and Rowland, {Megan M.} and Heinrich, {Megan L.} and Augustine Goba and Mambu Momoh and Grant, {Donald S.} and Mohamed Fullah and Khan, {Sheik Humarr} and Robinson, {James E.} and Thomas Geisbert and Garry, {Robert F.}",

year = "2016",

month = sep,

day = "1",

doi = "10.1016/j.antiviral.2016.08.012",

language = "English (US)",

volume = "133",

pages = "218--222",

journal = "Antiviral Research",

issn = "0166-3542",

publisher = "Elsevier",

}

TY - JOUR

T1 - Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies

AU - Cross, Robert

AU - Mire, Chad

AU - Branco, Luis M.

AU - Geisbert, Joan B.

AU - Rowland, Megan M.

AU - Heinrich, Megan L.

AU - Goba, Augustine

AU - Momoh, Mambu

AU - Grant, Donald S.

AU - Fullah, Mohamed

AU - Khan, Sheik Humarr

AU - Robinson, James E.

AU - Geisbert, Thomas

AU - Garry, Robert F.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.

AB - Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.

UR - http://www.scopus.com/inward/record.url?scp=84983735536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983735536&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2016.08.012

DO - 10.1016/j.antiviral.2016.08.012

M3 - Article

C2 - 27531367

AN - SCOPUS:84983735536

VL - 133

SP - 218

EP - 222

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

ER -